Clinical Trial Update: Surgical Conversion of Candonilimab (AK104) Plus Paclitaxel, S-1 and Apatinib for Unresectable Advanced G/GEJ Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating surgical conversion with Candonilimab (AK104) plus Paclitaxel, S-1, and Apatinib for unresectable advanced gastric/GEJ cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Cancer

Drugs mentioned

• Apatinib (apatinib)
• Candonilimab
• PACLITAXEL (PACLITAXEL)
• S-1 (tegafur/gimeracil/oteracil)

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: Gastric Cancer | Phase 2 | Status: UNKNOWN